2/3-FEA Pellets 40mg/120mg
€ 21,25 – € 360,00Price range: € 21,25 through € 360,00
2/3-FEA Pellets 40mg/120mg are described as compressed research preparations containing two positional fluoroethamphetamine isomers: 2-FEA and 3-FEA.
Both compounds belong to the substituted amphetamine family and are fluorinated N-ethylamphetamine derivatives.
The supplied source reports a labeled composition of 40mg 2-FEA and 120mg 3-FEA per pellet, giving a combined nominal analyte quantity of 160mg.
These figures are labeled specifications, not independently verified finished-unit assay results.
The described research context includes chemical identity assessment, chromatographic differentiation of positional isomers, spectral characterization, and investigation of multi-analyte analytical systems.
The source reports molecular formula C11H16FN and molecular weight approximately 181.25 g/mol for each neutral isomer.
It also claims component purities of approximately 98–99%, third-party testing, batch tracking, and ISO-aligned production.
No actual batch-specific analytical reports or manufacturing certifications were supplied.
Component identities, CAS assignments, chemical forms, finished-unit content, content uniformity, excipients, and stability remain unverified.
The pellets are not established as certified reference materials or validated quantitative calibration mixtures.
For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.
2/3-FEA Pellets 40mg/120mg – Dual-Isomer Research Material
2/3-FEA Pellets 40mg/120mg – Product Overview
2/3-FEA Pellets 40mg/120mg is the supplied catalog designation for a compressed-pellet research preparation associated with two positional isomers of fluoroethamphetamine.
The named components are 2-fluoroethamphetamine, abbreviated 2-FEA, and 3-fluoroethamphetamine, abbreviated 3-FEA.
Both compounds belong to the substituted amphetamine family.
They share the same molecular formula but differ in the position of the fluorine substituent on the aromatic ring. 2/3-FEA Pellets 40mg/120mg
The supplied source describes a single finished pellet containing labeled quantities of both isomers.
The stated component quantities are source-provided specifications rather than independently confirmed analytical measurements.
No finished-unit assay, component-specific quantitative report, or content-uniformity study accompanied the information.
The source positions the preparation for controlled analytical and non-clinical laboratory research.
The stated scientific contexts include chemical identification, chromatographic characterization, spectral differentiation, and investigation of positional-isomer analytical systems.
These potential research contexts should not be confused with verified analytical performance of the actual finished pellets.
The supplied information also refers to independent testing, batch records, and Certificate of Analysis documentation. 2/3-FEA Pellets 40mg/120mg
However, no supporting laboratory certificates or batch-specific analytical results were provided.
The finished preparation is not established as a certified reference material, validated quantitative calibration mixture, or approved pharmaceutical product.
Chemical Identity & Classification
The designation 2/3-FEA refers to a combination of two distinct chemical compounds rather than a single molecular entity.
Both compounds are fluorinated N-ethylamphetamine derivatives.
2-FEA contains a fluorine substituent at the ortho position of the aromatic ring.
3-FEA contains a fluorine substituent at the meta position.
The supplied chemical information includes:
| Characteristic | 2-FEA | 3-FEA |
|---|---|---|
| Chemical name | 2-Fluoroethamphetamine | 3-Fluoroethamphetamine |
| Structural description | N-Ethyl-1-(2-fluorophenyl)propan-2-amine | N-Ethyl-1-(3-fluorophenyl)propan-2-amine |
| Reported CAS number | 3871-89-4 | 54982-43-3 |
| Reported molecular formula | C11H16FN | C11H16FN |
| Calculated molecular weight | Approximately 181.25 g/mol | Approximately 181.25 g/mol |
| Labeled quantity | 40mg | 120mg |
The combined labeled analyte quantity is 160mg per pellet.
This arithmetic total does not establish the actual finished-unit assay or total pellet mass.
The reported molecular formula and molecular weight are internally consistent for the neutral compounds.
However, the source does not establish whether either ingredient is present as a free base or a salt.
It also does not establish the stereochemical composition of either isomer.
The reported 3-FEA CAS number differs from another supplier-provided identifier previously associated with the same named compound. 2/3-FEA Pellets 40mg/120mg
That discrepancy should be resolved against verified structural records before definitive publication.
Because the product is a mixture, it should not be assigned a single molecular formula, molecular weight, or CAS number for the complete finished preparation.
Researchers may consult PubChem for public chemical-reference information, ensuring that any selected record corresponds to the relevant positional isomer, stereochemistry, and chemical form.
Chemical & Physical Characteristics
The supplied source describes the product as off-white to beige compressed pellets of uniform size and shape.
No actual product-specific physical inspection report, image verification, or batch appearance record was supplied.
The reported appearance therefore remains a supplier-provided description.
A compressed pellet is a finished preparation that may contain multiple analytes together with additional formulation components. 2/3-FEA Pellets 40mg/120mg
The source does not identify the excipient composition, total unit mass, pellet dimensions, compression characteristics, or manufacturing method.
The two named compounds are positional isomers.
Their molecular formulas are identical, but the position of the fluorine substituent differs.
This structural distinction is relevant to analytical identification and differentiation.
The source describes general solubility in common organic solvents.
However, no product-specific solubility measurements, solvent compatibility records, or finished-pellet extraction studies were supplied.
No validated dissolution, recovery, or stability data were provided for the complete preparation.
The source also does not establish whether both analytes are distributed uniformly within each finished pellet.
Consequently, no definitive claim is made about the physical behavior or analytical recovery of the finished mixture.
Purity & Analytical Verification
The supplied source claims typical component purities of approximately 98–99%.
It also refers to independent analytical verification and low impurity levels.
No actual batch-specific Certificate of Analysis, chromatogram, mass spectrum, NMR spectrum, impurity profile, or independent laboratory report was supplied.
The claimed component purities and impurity limits therefore remain unverified.
For 2/3-FEA Pellets 40mg/120mg, ingredient purity and finished-unit composition are separate analytical characteristics.
An ingredient-purity result does not independently establish the actual quantity of either isomer in a finished pellet.
Likewise, the nominal component ratio does not establish content uniformity across a batch.
The source refers to HPLC, GC-MS, LC-MS/MS, and NMR spectroscopy as analytical techniques relevant to characterization.
However, no product-specific results were supplied demonstrating the separation, identification, or quantitative recovery of both isomers from the finished preparation.
Because 2-FEA and 3-FEA share a molecular formula, analytical identification requires attention to their structural distinction.
The source does not establish a validated isomer-specific quantitative method, assigned reference values, or measurement uncertainty.
The preparation should therefore not be described as a certified quantitative reference mixture.
Any definitive claims about purity, identity, composition, or uniformity require supporting analytical records for the actual batch.
Quality Control & Batch Integrity
The source refers to third-party testing, batch-specific tracking, complete documentation, ICH-aligned practices, and ISO-aligned production conditions.
These are supplier-provided quality-assurance claims.
No actual third-party report, batch record, manufacturing audit, or ISO certification was supplied.
The claims therefore remain unverified. 2/3-FEA Pellets 40mg/120mg
For a dual-isomer preparation, batch documentation should distinguish the identity and analytical characteristics of each ingredient from the characteristics of the finished pellet.
The source does not establish whether the stated component quantities were independently measured after formulation.
It also does not provide evidence of finished-unit content uniformity or batch-to-batch consistency.
For 2/3-FEA Pellets 40mg/120mg, the distinction between nominal composition and verified finished-unit composition is particularly important because the two components are positional isomers.
The Research Use Only designation describes intended positioning but does not independently demonstrate quality, traceability, or validated analytical performance.
Claims concerning independent verification, ISO compliance, ICH alignment, and batch consistency should be supported by actual records.
Safety, Handling & Laboratory Precautions
2-FEA and 3-FEA are synthetic substituted amphetamines associated with stimulant-class pharmacological activity and toxicological uncertainty.
The supplied source does not provide a complete toxicological assessment of either component or their combined preparation.
The presence of multiple active compounds introduces additional uncertainty concerning combined hazards and unintended exposure.
Laboratory personnel should consult applicable chemical-safety documentation and institutional procedures before receiving or examining the material. 2/3-FEA Pellets 40mg/120mg
Relevant precautions include restricted access, appropriate protective equipment, contamination prevention, accidental-exposure procedures, and chemical-waste management.
The compressed-pellet presentation does not establish safety for human or veterinary exposure.
The material should remain secured against unauthorized access and separated from food, beverages, and non-research environments.
Because the actual chemical forms, component purities, and finished-unit contents have not been independently confirmed, laboratory records should clearly distinguish supplier-provided specifications from verified findings.
Any accidental exposure or contamination incident should be managed according to institutional emergency procedures.
Packaging, Labeling & Storage
The supplied source describes light-resistant, moisture-resistant packaging, batch-aware handling, tracking, and professional shipment arrangements.
No actual packaging specification, container-validation report, or shipment-condition record was supplied.
The source recommends storage in a cool, dry, low-humidity environment protected from light.
It also suggests refrigeration at approximately 2–8°C.
No validated stability study was provided for the complete dual-isomer pellet preparation.
The suggested temperature range therefore cannot be presented as a verified requirement or as evidence of a particular shelf life.
For 2/3-FEA Pellets 40mg/120mg, laboratory inventory records should preserve the product designation, any available batch identifier, receipt details, and relevant storage observations.
The component quantities should be recorded as labeled specifications unless independently verified.
Packaging and environmental requirements should be assessed using available safety documentation, relevant stability evidence, and institutional procedures.
Intended Research Use & Market Positioning
The supplied scientific context places the 2/3-FEA combination within analytical research involving positional-isomer identification and differentiation of fluorinated N-ethylamphetamine derivatives.
The two named ingredients share a molecular formula but differ in the aromatic position of the fluorine substituent.
This structural distinction is relevant to chemical identity records and analytical interpretation.
The source describes interest in chromatographic characterization, forensic analytical studies, and investigation of related substituted amphetamines. 2/3-FEA Pellets 40mg/120mg
However, no product-specific analytical validation, combined pharmacological dataset, or stability study was supplied for the actual pellets.
The Raw Lab Chems catalog identifies 2/3-FEA Pellets as the product listing discussed here.
For related single-component catalog context, the supplied source also identifies 2-FEA Pellets and 3-FEA Pellets.
These related listings refer to separate named compounds rather than the dual-isomer preparation described here.
The supplied information does not establish equivalent chemical purity, finished-unit content, excipient composition, or analytical performance across these products.
The catalog references should not be interpreted as evidence of certified reference-material status or validated quantitative equivalence.
Ordering, Availability & Fulfillment
The supplied source describes professional packaging, international shipping, tracking, and secure handling arrangements.
No current inventory record, confirmed pack-size listing, carrier agreement, shipment authorization, or verified delivery information was supplied.
Consequently, no availability, delivery-time, customs-clearance, or transportation-compliance guarantee is asserted.
2-FEA and 3-FEA may be subject to controlled-substance, analogue, pharmaceutical, or other chemical regulations depending on the jurisdiction.
The combined preparation may also be subject to additional regulatory considerations.
Institutional acquisition, possession, transportation, importation, and exportation must be assessed under applicable laws.
Research-only labeling does not establish a legal exemption.
Legal & Regulatory Disclaimer
For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications. 2/3-FEA Pellets 40mg/120mg
The supplied product is described as a dual-isomer preparation containing 2-fluoroethamphetamine and 3-fluoroethamphetamine.
Possession, acquisition, transfer, transportation, importation, exportation, and laboratory investigation of these substances or their mixtures may be restricted or prohibited depending on the jurisdiction.
The supplied information does not establish universal legal status or regulatory authorization.
Institutions remain responsible for determining applicable legal requirements and obtaining any necessary permissions.
No medical approval, consumer-use authorization, or regulatory exemption is implied by this description.
| Quantity (pellets) |
5 ,10 ,25 ,50 ,100 |
|---|
You must be logged in to post a review.

Reviews
There are no reviews yet.